Figure 1



Treatment: BCG = 5 x 10E5 CFU BCG (range 2 - 8 x 10E5),
Group 1 = 5 x 10E3 CFU VPM1002 (range 2 - 8 x 10E3),
Group 2 = 5 x 10E4 CFU VPM1002 (range 2 - 8 x 10E4),
Group 3 = 5 x 10E5 CFU VPM1002 (range 2 - 8 x 10E5).

Figure 2

Mean Induration Size by Treatment Group and Study Day



Treatment: BCG = 5 x 10E5 CFU BCG (range 2 - 8 x 10E5),
Group 1 = 5 x 10E3 CFU VPM1002 (range 2 - 8 x 10E3),
Group 2 = 5 x 10E4 CFU VPM1002 (range 2 - 8 x 10E4),
Group 3 = 5 x 10E5 CFU VPM1002 (range 2 - 8 x 10E5).

Figure 3

Mean Changes from Baseline for IFN-γ-Response after Stimulation with Ag85B in Naïve Subjects



Figure 4

Mean Changes from Baseline for IFN-γ-Response after Stimulation with Ag85B in Pre-Immunized Subjects



Figure 5


Change from Baseline of Single Multifunctional CD4+ T cells in Naïve Subjects
A
B
C
D
BCG 5x10e5 CFU
VPM1002 5x10e5 CFU
Change from Baseline (%)
Day 29
Day 57
Month 6
Time post immunization

Figure 1

Mean Induration Size by Treatment Group and Study Day



Treatment: BCG = 5 x 10E5 CFU BCG (range 2 - 8 x 10E5),
Group 1 = 5 x 10E3 CFU VPM1002 (range 2 - 8 x 10E3),
Group 2 = 5 x 10E4 CFU VPM1002 (range 2 - 8 x 10E4),
Group 3 = 5 x 10E5 CFU VPM1002 (range 2 - 8 x 10E5).

Figure 2

Mean Erythema Size by Treatment Group and Study Day



Treatment: BCG = 5 x 10E5 CFU BCG (range 2 - 8 x 10E5),
Group 1 = 5 x 10E3 CFU VPM1002 (range 2 - 8 x 10E3),
Group 2 = 5 x 10E4 CFU VPM1002 (range 2 - 8 x 10E4),
Group 3 = 5 x 10E5 CFU VPM1002 (range 2 - 8 x 10E5).

Figure 3

Mean Changes from Baseline for IFN-γ-Response after Stimulation with Ag85B in Naïve Subjects



Figure 4

Mean Changes from Baseline for IFN-γ-Response after Stimulation with Ag85B in Pre-Immunized Subjects



Figure 5


Change from Baseline of Single Multifunctional CD4+ T cells in Naïve Subjects
A
B
C
D
BCG 5x10e5 CFU
VPM1002 5x10e5 CFU
Change from Baseline (%)
Day 29
Day 57
Month 6
Time post immunization